Loading...

Allena Pharmaceuticals, Inc.

ALNA•NASDAQ
Healthcare
Biotechnology
$0.07
$0.002(3.16%)

Allena Pharmaceuticals, Inc. (ALNA) Company Profile & Overview

Explore Allena Pharmaceuticals, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Allena Pharmaceuticals, Inc. (ALNA) Company Profile & Overview

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

SectorHealthcare
IndustryBiotechnology
CEOLouis Brenner

Contact Information

https://www.allenapharma.com
16174674577
1 Newton Executive Park Ste 202, Newton, MA, 02462

Company Facts

12 Employees
IPO DateNov 2, 2017
CountryUS

Frequently Asked Questions

;